MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Nutritional traits in the prodromal phase on Parkinson’s disease in community-dwelling older adults in Japan

    T. Yamaguchi, R. Nozaki, K. Taguchi, Y. Suzuki, K. Takahashi, K. Takahashi, K. Iwaoka, Y. Sato, T. Terauchi, H. Akasaka, N. Ishizuka, T. Maeda (Iwate, Japan)

    Objective: The objects of this study is to clarify the relationship between nutritional traits and the prodromal phase of PD in the community-dwelling older adults.…
  • 2023 International Congress

    Role of the direct subthalamo-cerebellar tract in memory and learning: Implications for the pathophysiology of late-stage Parkinson’s Disease

    V. Radhakrishnan, C. Gallea, S. Krishnan, B. Thomas, C. Kesavadas, A. Kishore (Trivandrum, India)

    Objective: To study the role of the recently identified direct subcortical cerebellum basal ganglia (C-BG) network in the pathophysiology of Parkinson’s Disease (PD). Background: Even…
  • 2023 International Congress

    Decreased occurrence of dyskinesia when combining amantadine to L-DOPA in early Parkinson disease (PD): the PREMANDYSK trial

    O. Rascol, F. Ory-Magne, JP. Azulay, L. Defebvre, JL. Houeto, D. Maltete, P. Remy, A. Foubert-Samier, A. Sommet, C. Thalamas, S. Thobois, JC. Corvol, N. Ns-Park/fcrin (Toulouse, France)

    Objective: To assess amantadine effects on dyskinesia and other PD symptoms when adjunct to L-DOPA in early PD. Background: Amantadine is efficacious on L-DOPA-induced dyskinesia…
  • 2023 International Congress

    Therapeutic effects of citral nanoliposome on Parkinson’s treatment in a rat model: Modulation via neurochemical, inflammatory and antioxidant pathways

    N. Moradikor, M. Haghipanah, W. Mohamed (Tbilisi, Georgia)

    Objective: The present study aimed to assess the effects of citral nanoliposome on Parkinson's treatment in a rat model. Background: Parkinson's disease is the most…
  • 2023 International Congress

    Dopamine transporter in the brain is linked to irritable bowel syndrome in Parkinson´s disease

    K. Murtomäki, J. Joutsa, T. Mertsalmi, E. Jaakkola, E. Mäkinen, R. Levo, M. Eklund, S. Nuuttila, E. Pekkonen, T. Noponen, T. Ihalainen, V. Kaasinen, F. Scheperjans (Helsinki, Finland)

    Objective: To assess correlations between gastrointestinal symptoms and dopamine transporter (DAT) changes in striatal and extrastriatal areas in Parkinson´s disease (PD) patients. Background: Gastrointestinal symptoms…
  • 2023 International Congress

    Clinic versus home dose optimization of apomorphine sublingual film in Parkinson’s Disease: cross-study comparison of safety

    SH. Isaacson, J. Kassubek, R. Pahwa, E. Pappert, S. Wu, C. Denecke Muhr (Boca Raton, USA)

    Objective: To compare the safety profile of clinic versus home dose optimization of apomorphine sublingual film (SL-APO) in patients with Parkinson’s disease experiencing OFF episodes.…
  • 2023 International Congress

    Psychosocial factors impacting participation in a time-intensive deep brain stimulation study of individuals with Parkinson’s disease and dystonia

    A. Hahn, S. Cernera, C. Racine, S. Little, P. Starr (San Francisco, USA)

    Objective: To evaluate psychosocial factors impacting the number of hours of participation in the first five months of a time-intensive deep brain stimulation (DBS) study.…
  • 2023 International Congress

    Building a consensus conceptual model of meaningful symptoms and impacts in early Parkinson’s disease

    J. Adams, J. Mammen, C. Kopil, Y. Xiao, D. Stephenson, T. Simuni (Rochester, USA)

    Objective: To develop a consensus based conceptual model of meaningful symptoms and impacts in early Parkinson’s disease (PD) through aligning of PD qualitative research carried…
  • 2023 International Congress

    Operationalising goal setting as an outcome measure: Experience from the PRIME-UK randomised controlled trial

    E. Tenison, K. Lloyd, Y. Ben-Shlomo, E. Henderson (Bristol, United Kingdom)

    Objective: To select a suitable primary outcome for the evaluation of a multicomponent intervention for people with parkinsonism. Background: The multicomponent PRIME model of care,…
  • 2023 International Congress

    Effects of GBA1 mutations and STN-DBS on response inhibition in Parkinson’s disease

    A. Almelegy, S. Gunda, S. Buyske, M. Rosenbaum, S. Sani, M. Afshari, L. Metman, C. Goetz, D. Hall, M. Mouradian, G. Pal (New Brunswick, USA)

    Objective: To determine specific pattern of cognitive dysfunction in Parkinson’s disease (PD) patients who are glucocerebrosidase mutation carriers (PD-GBA1) compared with non-mutation carriers with and…
  • « Previous Page
  • 1
  • …
  • 99
  • 100
  • 101
  • 102
  • 103
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Kratom withdrawal induced orobuccal dyskinesia
  • Welcome to the MDS Abstracts Site
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley